Details

Autor(en) / Beteiligte

• Johnson, Douglas B
• Atkins, Michael B
• Hennessy, Cassandra
• Wise-Draper, Trisha
• Heilman, Hannah
• Awosika, Joy
• Bakouny, Ziad
• Labaki, Chris
• Saliby, Renee Maria
• Hwang, Clara
• Singh, Sunny R K
• Balanchivadze, Nino
• Friese, Christopher R
• Fecher, Leslie A
• Yoon, James J
• Hayes-Lattin, Brandon
• Bilen, Mehmet A
• Castellano, Cecilia A
• Lyman, Gary H
• Tachiki, Lisa
• Shah, Sumit A
• Glover, Michael J
• Flora, Daniel B
• Wulff-Burchfield, Elizabeth
• Kasi, Anup
• Abbasi, Saqib H
• Farmakiotis, Dimitrios
• Viera, Kendra
• Klein, Elizabeth J
• Weissman, Lisa B
• Jani, Chinmay
• Puc, Matthew
• Fahey, Catherine C
• Reuben, Daniel Y
• Mishra, Sanjay
• Beeghly-Fadiel, Alicia
• French, Benjamin
• Warner, Jeremy L

Titel

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Ist Teil von

• BMC cancer, 2023-03, Vol.23 (1), p.265-265, Article 265

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35). Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.